The biopharmaceutical company Reig Jofre, a member of Catalonia.health, has announced the consolidation of its stake in Leanbio, a biotechnology company specialising in the development and production of biotechnological active pharmaceutical ingredients and also a member of Catalonia.health. Through this transaction, Reig Jofre increases its shareholding from 47% to 85% with a total investment of €3.5 million, while the remaining 15% remains in the hands of the founding team and specialised shareholders.
The acquisition represents a strategic step in the evolution of Reig Jofre’s business model, expanding its capacity to cover the entire biological drug lifecycle, from active ingredient development to the final sterile injectable product under GMP standards. Leanbio contributes differentiated technological capabilities in the development, characterisation and production of recombinant proteins, antibodies, plasmid DNA and RNA-based technologies, strengthening the group’s value proposition.
This integration is the result of a collaboration that began in 2018 with the creation of the Syna Therapeutics joint venture and was subsequently reinforced through several strategic investments. Among these, a €6.6 million investment stands out for the construction of a new GMP-certified biotechnological active ingredient production facility in Sant Quirze del Vallès, which is expected to begin operations in mid-2026.
Ignasi Biosca, CEO of Reig Jofre, stated: “This transaction is a strategic milestone for Reig Jofre. We are strengthening our vertical integration in biotechnology and consolidating a unique platform that combines Leanbio’s expertise in the development of biotechnological active pharmaceutical ingredients with our industrial capabilities in sterile injectables. In this context, the integration of Leanbio positions us not only as a fully integrated player across the value chain, but also as a strategic competitor in a sector that we expect to grow over the coming decade.”
Comments